Show simple item record

dc.contributor.authorMutai, Peggoty
dc.contributor.authorBreuzard, Gilles
dc.contributor.authorPagano, Alessandra
dc.contributor.authorAllegro, Diane
dc.contributor.authorPeyrot, Vincent
dc.contributor.authorChibale, Kelly
dc.date.accessioned2017-04-03T08:21:13Z
dc.date.available2017-04-03T08:21:13Z
dc.date.issued2017
dc.identifier.citationBioorganic & Medicinal Chemistry Volume 25, Issue 5, 1 March 2017, Pages 1652–1665en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S0968089616310732
dc.identifier.urihttp://hdl.handle.net/11295/100751
dc.description.abstractThe synthesis of twenty-six 4-arylcoumarin analogues of combretastatin A-4 (CA-4) led to the identification of two new compounds (25 and 26) with strong cytotoxic activity. Both compounds had a high cytotoxic effect on a CA-4-resistant colon adenocarcinoma cell line (HT29D4). The compounds affected cell cycle progression characterized by a mitotic block. The activity of these compounds against microtubules both in vitro and in cells was examined and both compounds were found to potently inhibit in vitro microtubule formation via a sub-stoichiometric mode like CA-4. By immunofluorescence, it was observed that both compounds induced strong microtubule network disruption. Our results provide a strong experimental basis to develop new potent anti-tubulin molecules targeting CA-4-resistant cancer cells.en_US
dc.language.isoenen_US
dc.publisherUniversity of Nairobien_US
dc.titleSynthesis and biological evaluation of 4 arylcoumarin analogues as tubulin-targeting antitumor agentsen_US
dc.typeArticleen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record